Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$16.55
$19.31
$13.46
$31.04
$470.02M0.91291,778 shs1.32 million shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$3.50
$4.46
$2.56
$12.72
$169.27M1.99715,750 shs567,464 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
$29.36
$4.30
$31.70
$497.27MN/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
$4.96
+2.1%
$5.18
$2.32
$6.67
$490.25M0.391.90 million shs1,773 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
0.00%-15.86%-20.62%+17.13%-10.69%
LifeMD, Inc. stock logo
LFMD
LifeMD
0.00%-5.66%-28.13%-30.00%-64.79%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%0.00%-0.02%+2,935,499,900.00%
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
0.00%-2.41%-7.95%+20.00%+30.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$16.55
$19.31
$13.46
$31.04
$470.02M0.91291,778 shs1.32 million shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$3.50
$4.46
$2.56
$12.72
$169.27M1.99715,750 shs567,464 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
$29.36
$4.30
$31.70
$497.27MN/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
$4.96
+2.1%
$5.18
$2.32
$6.67
$490.25M0.391.90 million shs1,773 shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
0.00%-15.86%-20.62%+17.13%-10.69%
LifeMD, Inc. stock logo
LFMD
LifeMD
0.00%-5.66%-28.13%-30.00%-64.79%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%0.00%-0.02%+2,935,499,900.00%
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
0.00%-2.41%-7.95%+20.00%+30.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
2.20
Hold$27.0063.14% Upside
LifeMD, Inc. stock logo
LFMD
LifeMD
2.60
Moderate Buy$9.14161.22% Upside
Charming Medical Ltd stock logo
MCTA
Charming Medical
1.00
SellN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
2.60
Moderate Buy$8.5074.90% Upside

Current Analyst Ratings Breakdown

Latest LFMD, FLGT, MCTA, and TOI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
Reiterated RatingSell (D-)
7/17/2026
LifeMD, Inc. stock logo
LFMD
LifeMD
DowngradeHoldStrong Sell
7/13/2026
Charming Medical Ltd stock logo
MCTA
Charming Medical
UpgradeSell (E+)Sell (D-)
7/9/2026
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
Boost Price TargetBuy$8.00 ➝ $9.00
7/6/2026
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Reiterated RatingSell (E+)
7/6/2026
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
Initiated CoverageBuy$10.00
6/29/2026
Charming Medical Ltd stock logo
MCTA
Charming Medical
Reiterated RatingSell (E+)
6/17/2026
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
Boost Price TargetBuy$5.00 ➝ $7.00
6/8/2026
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
Boost Price TargetBuy$7.00 ➝ $8.00
5/27/2026
LifeMD, Inc. stock logo
LFMD
LifeMD
Reiterated RatingBuy
5/26/2026
LifeMD, Inc. stock logo
LFMD
LifeMD
Reiterated RatingBuy$10.00
(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$322.67M1.46N/AN/A$35.80 per share0.46
LifeMD, Inc. stock logo
LFMD
LifeMD
$193.33M0.88N/AN/A$0.48 per share7.29
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
$502.73M0.96N/AN/A($0.16) per share-30.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$60.51M-$2.82N/AN/AN/A-26.05%-4.93%-4.50%N/A
LifeMD, Inc. stock logo
LFMD
LifeMD
$14.35M$0.0570.0119.44N/A2.37%-150.88%-22.59%8/5/2026 (Estimated)
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/AN/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
-$60.61M-$0.37N/AN/AN/A-7.42%N/A-24.68%8/6/2026 (Estimated)

Latest LFMD, FLGT, MCTA, and TOI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
-$0.07N/AN/AN/A$155.28 millionN/A
8/5/2026Q2 2026
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.1457N/AN/AN/A$49.16 millionN/A
7/30/2026Q2 2026
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$0.46-$0.58-$0.12-$1.05$94.00 million$85.39 million
5/7/2026Q1 2026
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
-$0.07-$0.02+$0.05-$0.02$142.10 million$147.44 million
5/6/2026Q1 2026
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.14-$0.20-$0.06-$0.20$48.84 million$50.16 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
N/AN/AN/AN/AN/A
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/A
6.34
6.34
LifeMD, Inc. stock logo
LFMD
LifeMD
N/A
1.04
0.98
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
N/A
1.47
1.17

Institutional Ownership

CompanyInstitutional Ownership
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
48.06%
LifeMD, Inc. stock logo
LFMD
LifeMD
35.52%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
36.86%

Insider Ownership

CompanyInsider Ownership
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
36.18%
LifeMD, Inc. stock logo
LFMD
LifeMD
17.22%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
4.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
1,31528.40 million18.13 millionOptionable
LifeMD, Inc. stock logo
LFMD
LifeMD
23048.36 million40.04 millionOptionable
Charming Medical Ltd stock logo
MCTA
Charming Medical
4916.94 millionN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
66098.84 million94.49 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fulgent Genetics stock logo

Fulgent Genetics NASDAQ:FLGT

$16.55 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$16.55 +0.00 (+0.01%)
As of 07/31/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

LifeMD stock logo

LifeMD NASDAQ:LFMD

$3.50 0.00 (0.00%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$3.54 +0.04 (+1.29%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

Charming Medical stock logo

Charming Medical NASDAQ:MCTA

$29.36 0.00 (0.00%)
As of 07/31/2026

We are a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. We offer a wide range of beauty, wellness, and postpartum services and products rooted and influenced by the principles and practices of TCM, such as the use of herbal ingredients, acupuncture techniques, Tuina massage, and dietary guidance. Operating under the Beauty Lab Group (“Beauty Lab”) brand, our Operating Subsidiaries in Hong Kong offer a wide range of TCM-inspired beauty, wellness, and postpartum therapies and products through our four wellness centers in Hong Kong. Our services are designed to meet diverse health improvement needs, including alleviating premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal care, breast health, and other common women’s health conditions. We believe that our TCM-inspired herbal therapies can help balance the female endocrine system and improve women’s constitution and overall health. Additionally, the Operating Subsidiaries offer TCM-inspired therapies tailored to men. We offer a wide range of beauty, wellness, and postpartum services for women with a focus on utilizing TCM approaches in addressing women’s health issues. Our beauty, wellness, and postpartum services include but are not limited to womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox therapy, agarwood moxibustion therapy, TCM-inspired prenatal massage, and Indonesian traditional abdominal binding. In addition, under the “Beauty Lab” brand, we also offer supplements products, including (i) TCM-inspired supplements products, such as Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets, designed to support uterine health, improve physical weakness, and balance endocrine functions for female customers; and (ii) beauty products, including ginseng soothing anti-allergy moisturizing wash, which provide comprehensive care for skin issues, and scalp health. Moreover, we also offer consultancy services to provide TCM-inspired therapy technical training and dietary therapy training to other well-established and reputable beauty salons, massage centers, and similar institutions. In March 2025, we launched a franchise model for our Beauty Lab brand, granting exclusive rights to independent third parties (the “Franchisees”) to operate branded beauty and wellness outlets. Franchisees are authorized to offer services such as scalp and hair care and women’s wellness services under the Beauty Lab brand. We derive franchise-related revenue mainly from initial franchise fees, royalty and promotional fees, brand management fees, training and administration fees. As of March 31, 2025 and as of the date of this prospectus, we had 1 and 3 franchisees, respectively. We generated revenue of $6,221,751 and $6,015,375, respectively, and achieved a net income of $1,199,085 and $821,743, respectively, for the years ended March 31, 2025 and 2024. We generated revenue primarily through the following: (i) beauty, wellness, and postpartum services; (ii) sales of products; (iii) consultancy services; and (iv) franchise activities. For the fiscal years ended March 31, 2025 and 2024, the revenue from beauty, wellness, and postpartum services amounted to $5,967,277 and $5,813,814, representing 96.0% and 96.6% of total revenue, respectively. The revenue from sales of products was $207,766 and $88,992 for the fiscal years ended March 31, 2025 and 2024, representing 3.2% and 1.5% of total revenue, respectively. The revenue from consultancy services was nil and $112,569 for the fiscal years ended March 31, 2025 and 2024, representing 0% and 1.9% of total revenue, respectively. The revenue from franchise activities was $46,708 and nil for the fiscal years ended March 31, 2025 and 2024, representing 0.8% and 0% of total revenue, respectively. Our principal executive office is located Hong Kong.

Oncology Institute stock logo

Oncology Institute NASDAQ:TOI

$4.96 +0.10 (+2.06%)
As of 08:37 AM Eastern

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.